ECSP19046893A - Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip - Google Patents

Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip

Info

Publication number
ECSP19046893A
ECSP19046893A ECSENADI201946893A ECDI201946893A ECSP19046893A EC SP19046893 A ECSP19046893 A EC SP19046893A EC SENADI201946893 A ECSENADI201946893 A EC SENADI201946893A EC DI201946893 A ECDI201946893 A EC DI201946893A EC SP19046893 A ECSP19046893 A EC SP19046893A
Authority
EC
Ecuador
Prior art keywords
glucagon
trigonal
glp1
new compounds
gip receptors
Prior art date
Application number
ECSENADI201946893A
Other languages
English (en)
Inventor
Stefania Pfeiffer-Marek
Dieter Kadereit
Andreas Evers
Katrin Lorenz
Michael Wagner
Martin Bossart
Torsten Haack
Martin Lorenz
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ECSP19046893A publication Critical patent/ECSP19046893A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Nuevos compuestos como agonistas peptídicos trigonales de los receptores de GLP1/Glucagón/GIP La presente invención se refiere a agonistas trigonales de los receptores de GLP-1 / glucagón / GIP y a su uso médico, por ejemplo, en el tratamiento de trastornos del síndrome metabólico, incluyendo diabetes y obesidad, así como para la reducción del exceso de ingesta de alimentos.
ECSENADI201946893A 2016-12-02 2019-07-01 Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip ECSP19046893A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16306604 2016-12-02

Publications (1)

Publication Number Publication Date
ECSP19046893A true ECSP19046893A (es) 2019-07-31

Family

ID=57542935

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201946893A ECSP19046893A (es) 2016-12-02 2019-07-01 Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip

Country Status (23)

Country Link
US (1) US10538567B2 (es)
EP (1) EP3548508B1 (es)
JP (1) JP7100033B2 (es)
KR (1) KR102576872B1 (es)
CN (1) CN110023329B (es)
AR (1) AR110300A1 (es)
AU (1) AU2017367173B2 (es)
BR (1) BR112019011228A2 (es)
CA (1) CA3045377A1 (es)
CL (1) CL2019001465A1 (es)
CO (1) CO2019006917A2 (es)
CR (1) CR20190313A (es)
DO (1) DOP2019000068A (es)
EA (1) EA201991345A1 (es)
EC (1) ECSP19046893A (es)
IL (1) IL266984A (es)
MA (1) MA46955A (es)
MX (1) MX2019006429A (es)
PE (1) PE20191143A1 (es)
PH (1) PH12019501216A1 (es)
TW (1) TW201833132A (es)
UY (1) UY37506A (es)
WO (1) WO2018100134A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
SG11202010016QA (en) 2018-04-10 2020-11-27 Sanofi Aventis Deutschland Lixisenatide synthesis with capping
MX2020010716A (es) 2018-04-10 2021-03-09 Sanofi Aventis Deutschland Metodo para escindir de la fase solida peptidos unidos a una fase solida.
TW202015735A (zh) 2018-05-30 2020-05-01 法商賽諾菲公司 包含glp-1/升糖素/gip三重受體促效劑、連接子及透明質酸之接合物
WO2020130749A1 (ko) * 2018-12-21 2020-06-25 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
JP7761557B2 (ja) * 2019-10-04 2025-10-28 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、及びglp-1受容体及びgip受容体二重アゴニストを含む組成物及びその治療学的使用
KR20220100925A (ko) 2019-11-11 2022-07-18 베링거 인겔하임 인터내셔날 게엠베하 Npy2 수용체 작용제
TW202228762A (zh) * 2020-01-30 2022-08-01 美商美國禮來大藥廠 提派肽(tirzepatide)之治療用途
WO2022029231A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists
BR112023002608A2 (pt) * 2020-08-12 2023-05-09 Txp Pharma Ag Análogo de peptídeo de exendina-4, e, método para tratamento de diabetes mellitus tipo 2, obesidade e/ou intensificação da saciedade
WO2022035302A1 (ko) * 2020-08-14 2022-02-17 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물
CN114349828B (zh) * 2020-11-27 2023-12-08 江苏师范大学 Glp-1/胰高血糖素受体双重激动剂及其应用
GB202110809D0 (en) * 2021-07-27 2021-09-08 Imperial College Innovations Ltd Novel compounds
TWI921427B (zh) * 2020-12-16 2026-04-11 丹麥商西蘭製藥公司 Glp-1/glp-2雙重促效劑之醫藥組合物
AU2021399904B2 (en) * 2020-12-16 2024-09-05 Zealand Pharma A/S Pharmaceutical composition of glp-1/glp-2 dual agonists
IL301891A (en) * 2020-12-16 2023-06-01 Zealand Pharma As Drug composition of dual GLP-1/GLP-2 agonists
MX2023015250A (es) * 2021-06-25 2024-01-19 Lilly Co Eli Metodos para tratar la apnea obstructiva del sue?o.
KR20230004135A (ko) * 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
WO2023228156A1 (en) * 2022-05-27 2023-11-30 D&D Pharmatech Inc. Peptide compositions and methods of use threof
CN117417411B (zh) * 2022-09-28 2025-08-29 广东东阳光药业股份有限公司 Glp-1/gcg/gip三受体激动剂及其用途
IL324886A (en) * 2022-12-23 2026-01-01 Hanmi Pharmaceutical Co Ltd Novel triple glp-1/gip/glucagon receptor agonistand a pharmaceutical composition for preventing ortreating obesity comprising the same
WO2025049610A1 (en) * 2023-08-28 2025-03-06 Shattuck Labs, Inc. Multi-action peptides
CN117586374B (zh) * 2023-10-07 2024-11-29 深圳湾实验室 Glp-1r/gipr/gcgr三重激动剂类似物及其用途
CN119241684B (zh) * 2024-11-22 2025-02-25 徐州医科大学 一种肠促胰岛素类似物及其用途
WO2026125286A1 (en) * 2024-12-09 2026-06-18 Inventiva Combinations comprising lanifibranor and a glp-1/gip/glucagon triple receptor agonist for use in the treatment of liver diseases
WO2026082196A1 (zh) * 2025-03-13 2026-04-23 深圳碳云智肽药物科技有限公司 Glp-1、gip及gcg受体三重激动剂及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0314996A (pt) 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
US20080019911A1 (en) * 2005-04-20 2008-01-24 Aimin Xu Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4
EP1891105B1 (en) 2005-06-13 2012-04-11 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
ES2558842T3 (es) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
US20120148586A1 (en) * 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
SI2864350T1 (en) 2012-06-21 2018-08-31 Indiana University Research And Technology Corporation GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR
ES2602486T3 (es) * 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) * 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
AU2014345570B2 (en) * 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
TW201609798A (zh) 2013-12-13 2016-03-16 賽諾菲公司 Exendin-4胜肽類似物
TW201625670A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
WO2016198624A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
AR110301A1 (es) * 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip

Also Published As

Publication number Publication date
KR20190085141A (ko) 2019-07-17
KR102576872B1 (ko) 2023-09-12
JP2019536796A (ja) 2019-12-19
DOP2019000068A (es) 2019-05-31
AU2017367173A1 (en) 2019-07-18
EP3548508A1 (en) 2019-10-09
CN110023329A (zh) 2019-07-16
PH12019501216A1 (en) 2019-08-19
US20180155406A1 (en) 2018-06-07
CO2019006917A2 (es) 2019-07-10
MA46955A (fr) 2021-05-19
JP7100033B2 (ja) 2022-07-12
PE20191143A1 (es) 2019-09-02
CL2019001465A1 (es) 2019-10-18
EP3548508B1 (en) 2021-10-27
WO2018100134A1 (en) 2018-06-07
IL266984A (en) 2019-07-31
EA201991345A1 (ru) 2019-11-29
TW201833132A (zh) 2018-09-16
CN110023329B (zh) 2024-05-03
AR110300A1 (es) 2019-03-13
CA3045377A1 (en) 2018-06-07
UY37506A (es) 2018-06-29
BR112019011228A2 (pt) 2019-10-15
US10538567B2 (en) 2020-01-21
MX2019006429A (es) 2019-08-21
CR20190313A (es) 2019-09-11
AU2017367173B2 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
CO2019006917A2 (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
BR112019011144A2 (pt) compostos como agonistas peptídicos de receptor de glp1/glucagon/gip
AR099977A1 (es) Agonistas peptídicos dobles de los receptores del péptido similar al glucagón 1 (glp-1) y del receptor del glucagón (gcg), derivados de la exendina-4
UY35231A (es) Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/Glucagón
BR112016022754A2 (pt) derivados de exendina-4 como agonistas peptídicos duplos dos receptores de glp-1 / glucagon
AR098741A1 (es) Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón
UY35072A (es) Derivados de exendina-4 como agonistas duales de GLP1/glucagón
CL2017001760A1 (es) Compuestos co-agonistas de gip y glp-1
AR098738A1 (es) Análogos del péptido exendina-4 no acilados
AR091422A1 (es) Analogos peptidicos de la exendina 4
AR102712A1 (es) Agonistas parciales del receptor de insulina
BR112016023039A2 (pt) agonistas duplos dos receptores de glp-1 / glucagon derivados de exendina-4
CO7400885A2 (es) Análogos de glucagón
CL2020000812A1 (es) Semaglutida en la terapia médica.
MX2017009294A (es) Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida.
GT201500168A (es) Polipéptidos estabilizados del factor de crecimiento tipo insulina
CR20170470A (es) Tratamiento de pacientes con diabetes mellitus tipo 2
AR107282A1 (es) Agonista triple que tiene actividad para un receptor de glucagón, un receptor del péptido 1 similar al glucagón (glp-1) y un receptor de péptido insulinotrópico dependiente de glucosa (gip)